Evidence map›Paper›PMID 33241676›Full record

ArticleHaematologica2022

The epigenetic regulator RINF (CXXC5) maintains

Audrey Astori, Gabriel Matherat, Isabelle Munoz, Emilie-Fleur Gautier, Didier Surdez, Yaël Zermati, Frédérique Verdier, Sakina Zaidi, Vincent Feuillet, Amir Kadi and 10 more

Open access · goldAbstract read
In one paragraph

Article in Haematologica, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.3field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. CXXC5 is a ubiquitinated protein and is degraded by the ubiquitin-proteasome pathway.Protein science : a publication of the Protein Society · 2025
    Article
  2. Signal integrator function of CXXC5 in Cancer.Cell communication and signaling : CCS · 2025
    Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 7 institutions in 1 country.

Audrey AstoriUniversité de Paris, Institut Cochin, INSERM, CNRS, F-75014 Paris, France; Laboratory of Excellence GR-ex, Paris, France; Equipe Labellisée Ligue Nationale Contre le Cancer (LNCC), Paris.
Gabriel MatheratUniversité de Paris, Institut Cochin, INSERM, CNRS, F-75014 Paris, France; Laboratory of Excellence GR-ex, Paris, France; Equipe Labellisée Ligue Nationale Contre le Cancer (LNCC), Paris.
Isabelle MunozUniversité de Paris, Institut Cochin, INSERM, CNRS, F-75014 Paris, France; Laboratory of Excellence GR-ex, Paris, France; Equipe Labellisée Ligue Nationale Contre le Cancer (LNCC), Paris.
Emilie-Fleur GautierUniversité de Paris, Institut Cochin, INSERM, CNRS, F-75014 Paris, France; Laboratory of Excellence GR-ex, Paris, France; Equipe Labellisée Ligue Nationale Contre le Cancer (LNCC), Paris.
Didier SurdezEquipe Labellisée Ligue Nationale Contre le Cancer (LNCC), Paris, France; PSL Research University, Institut Curie Research Center, INSERM U830, Paris, France; SIREDO: Care, Innovation and Research for Children, Adolescents and Young Adults with Cancer, Institut Curie, Paris.
Yaël ZermatiUniversité de Paris, Institut Cochin, INSERM, CNRS, F-75014 Paris, France; Laboratory of Excellence GR-ex, Paris.
Frédérique VerdierUniversité de Paris, Institut Cochin, INSERM, CNRS, F-75014 Paris, France; Laboratory of Excellence GR-ex, Paris.
Sakina ZaidiEquipe Labellisée Ligue Nationale Contre le Cancer (LNCC), Paris, France; PSL Research University, Institut Curie Research Center, INSERM U830, Paris, France; SIREDO: Care, Innovation and Research for Children, Adolescents and Young Adults with Cancer, Institut Curie, Paris.
Vincent FeuilletUniversité de Paris, Institut Cochin, INSERM, CNRS, F-75014 Paris.
Amir KadiUniversité de Paris, Institut Cochin, INSERM, CNRS, F-75014 Paris.
Evelyne LauretUniversité de Paris, Institut Cochin, INSERM, CNRS, F-75014 Paris, France; Equipe Labellisée Ligue Nationale Contre le Cancer (LNCC), Paris.
Olivier DelattreEquipe Labellisée Ligue Nationale Contre le Cancer (LNCC), Paris, France; PSL Research University, Institut Curie Research Center, INSERM U830, Paris, France; SIREDO: Care, Innovation and Research for Children, Adolescents and Young Adults with Cancer, Institut Curie, Paris.
Carine LefèvreUniversité de Paris, Institut Cochin, INSERM, CNRS, F-75014 Paris, France; Laboratory of Excellence GR-ex, Paris.
Michaela FontenayUniversité de Paris, Institut Cochin, INSERM, CNRS, F-75014 Paris, France; Laboratory of Excellence GR-ex, Paris, France; Service d'Hématologie Biologique, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris, Centre-Université de Paris, Paris.
Evelyne Ségal-BendirdjianINSERM UMR-S 1124, Team: Cellular Homeostasis Cancer and Therapies, Université de Paris, Paris.
Isabelle Dusanter-FourtUniversité de Paris, Institut Cochin, INSERM, CNRS, F-75014 Paris, France; Equipe Labellisée Ligue Nationale Contre le Cancer (LNCC), Paris.
Didier BouscaryUniversité de Paris, Institut Cochin, INSERM, CNRS, F-75014 Paris, France; Equipe Labellisée Ligue Nationale Contre le Cancer (LNCC), Paris.
Olivier HermineLaboratory of Excellence GR-ex, Paris, France; Equipe Labellisée Ligue Nationale Contre le Cancer (LNCC), Paris, France; Université de Paris, Institut Imagine, INSERM, CNRS, F-75015, Paris.
Patrick MayeuxUniversité de Paris, Institut Cochin, INSERM, CNRS, F-75014 Paris, France; Laboratory of Excellence GR-ex, Paris, France; Equipe Labellisée Ligue Nationale Contre le Cancer (LNCC), Paris.
Frédéric PendinoUniversité de Paris, Institut Cochin, INSERM, CNRS, F-75014 Paris, France; Laboratory of Excellence GR-ex, Paris, France; Equipe Labellisée Ligue Nationale Contre le Cancer (LNCC), Paris. frederic.pendino@inserm.fr.
Laboratory of Excellence GR-Ex · FRInserm · FRCentre National de la Recherche Scientifique · FRInstitut Cochin · FRInstitut Curie · FRLa Ligue Contre le Cancer · FRUniversité Paris Cité · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The gene CXXC5, encoding a Retinoid-Inducible Nuclear Factor (RINF), is located within a region at 5q31.2 commonly deleted in myelodysplastic syndrome (MDS) and adult acute myeloid leukemia (AML). RINF may act as an epigenetic regulator and has been proposed as a tumor suppressor in hematopoietic malignancies. However, functional studies in normal hematopoiesis are lacking, and its mechanism of action is unknow. Here, we evaluated the consequences of RINF silencing on cytokineinduced erythroid differentiation of human primary CD34+ progenitors. We found that RINF is expressed in immature erythroid cells and that RINF-knockdown accelerated erythropoietin-driven maturation, leading to a significant reduction (~45%) in the number of red blood cells (RBCs), without affecting cell viability. The phenotype induced by RINF-silencing was TGFβ-dependent and mediated by SMAD7, a TGFβ- signaling inhibitor. RINF upregulates SMAD7 expression by direct binding to its promoter and we found a close correlation between RINF and SMAD7 mRNA levels both in CD34+ cells isolated from bone marrow of healthy donors and MDS patients with del(5q). Importantly, RINF knockdown attenuated SMAD7 expression in primary cells and ectopic SMAD7 expression was sufficient to prevent the RINF knockdowndependent erythroid phenotype. Finally, RINF silencing affects 5’-hydroxymethylation of human erythroblasts, in agreement with its recently described role as a Tet2- anchoring platform in mouse. Altogether, our data bring insight into how the epigenetic factor RINF, as a transcriptional regulator of SMAD7, may fine-tune cell sensitivity to TGFβ superfamily cytokines and thus play an important role in both normal and pathological erythropoiesis.

Indexed as

DNA-Binding ProteinsLeukemia, Myeloid, AcuteMyelodysplastic SyndromesSmad7 ProteinTranscription FactorsAdultAnimalsCell CycleEpigenesis, GeneticHumansMiceRNA, MessengerCXXC5 protein, humanCXXC5 protein, mouseDNA-Binding ProteinsRNA, MessengerSmad7 ProteinSMAD7 protein, humanSmad7 protein, mouseTranscription Factors

Identifiers

PMID33241676
PMCPMC8719099
OpenAlexW3106596346

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.